Orpea (emeis) Stock in 2026: Share Price, News and Outlook

Orpea stock no longer trades under that name: the French group of nursing homes (EHPAD), psychiatric clinics and post-acute care facilities is now called emeis, following the historic financial restructuring that came after the 2022 scandal. Listed on Euronext Paris as part of the SBF 120 under the ticker EMEIS, the stock trades at around €9.69 as of October 22, 2026 — and many investors still search for it under its former name, “Orpea“.

The Orpea stock story is one of rebuilding: after the collapse triggered by the book Les Fossoyeurs (“The Gravediggers”), massive capital increases and extreme dilution (−99.98% over five years, including the share consolidation), the group changed its name, its management and its scope. In 2026, guidance has been raised, first-half revenue is up 6% on a reported basis, and the exit from Latin America has been completed.

The five analysts who still cover the stock have a median price target of €16.44, nearly 70% above the current share price. This page gives you the full picture: share price, the story of the scandal and the restructuring, financials, risks and the buying decision.

Orpea (emeis) Share Price Live

emeis (formerly Orpea) is listed on Euronext Paris under the ticker EMEIS (ISIN FR001400NLM4). The stock is PEA-eligible. The live quote is shown in the widget below:

As of October 22, 2026, Orpea stock — still the name most investors search for — trades at €9.69 (−2.22% on the day), close to its 52-week low (€9.34); the 52-week high stands at €16.01. The recent trend has been harsh: −19.34% over one month, −30.84% over three months and −29.22% over one year.

Yet the group had reported a solid first half and raised its targets — since the summer, the market has been punishing the actual pace of the turnaround and the fading of speculative support. Over longer periods, the stock’s history must be read with care: the −98% over three years and −99.98% over five years include the share consolidation carried out during the restructuring, not just the fall in the share price. In other words, the long-term Orpea stock chart tells the story of the dilution of former shareholders as much as the company’s collapse.

To compare with other healthcare stocks, also see our analysis of Organogenesis stock and of Paratek Pharmaceuticals stock.

emeis (formerly Orpea) Stock Profile

Companyemeis S.A. (formerly Orpea)
Ticker / SymbolEMEIS (Euronext Paris)
ISINFR001400NLM4 (France — new post-restructuring identity)
Listing venuesEuronext Paris
SectorHealthcare — nursing homes (EHPAD), psychiatric clinics, post-acute care
PEA eligibilityYes
IndexSBF 120
DividendSuspended (€0 expected through 2027)
HeadquartersPuteaux, near Paris (France)

The business: a long-term care operator

emeis operates care facilities for dependent elderly people and specialized clinics, mainly in Europe. The business model rests on three revenue streams: accommodation (billed daily and indexed), care (reimbursed by health systems) and dependency support. It is a recurring-revenue, real-estate-intensive business — historically backed by sale-and-leaseback deals on its buildings, which fueled the pre-crisis financial engineering.

The 2024–2026 refocus has simplified this scope: the sale of the Latin American operations was completed for a total of around €111 million, and the group is concentrating on Western Europe, where it retains significant positions in France, Germany and the Benelux. The structural demand — population aging — did not disappear with the scandal; it is the core argument for the investors who have stayed.

Population aging, a structural driver

The sector’s core argument does not depend on the name of the listed company: in France, as across Western Europe, the share of people over 85 — the main users of nursing homes and long-term care — rises mechanically every year, while public capacity stagnates under budget constraints. Private operators that weather crises therefore still face a structurally growing market, driven by demographics rather than the economic cycle.

It was this “defensive through demand” profile that attracted investors to Orpea stock before 2022, along with a reputation as a steady income stock — a demand base comparable, in principle, to that of the major defensive healthcare stocks, including Sanofi stock, analyzed on this site.

Rebuilding the emeis story means precisely re-establishing that promise on sound accounting foundations: without excessive real-estate engineering, and with occupancy rates and quality of care recognized by public inspections — conditions without which structural demand does not turn into profits.

Why Did Orpea Stock Collapse?

The fall of Orpea stock was no market accident: it was a sector-wide scandal. In January 2022, the investigative book Les Fossoyeurs documented care failures in the group’s facilities and financial management optimized to the extreme. The impact was immediate: the stock lost most of its value within weeks, the authorities launched inspections (IGAS, the French social affairs inspectorate), and the trust of families, residents and investors collapsed.

Then came the funding crisis: heavily indebted and forced to sell property in a weak market, the group went through a series of capital increases and a debt restructuring in 2022–2024. Long-standing shareholders were diluted to the extreme, the share count was consolidated, and the stock took on a new market identity: Orpea became emeis in 2024, with a new ISIN — a stock market chapter comparable, in principle, to the one experienced by Atos stock over the same period: the same kind of dilutive rescue, the same change of identity, the same task of rebuilding trust.

The Les Fossoyeurs affair: what was revealed

Journalist Victor Castanet’s investigative book, published in late January 2022, describes a system: rationing of hygiene and care products, insufficient nursing staff and substandard medical care in several facilities — while the group paid generous dividends and made its real-estate structure ever more complex. IGAS inspections carried out the same year confirmed some of the failings, leading to repayments and tighter oversight of the private nursing home sector.

The legal consequences are ongoing: investigations were opened after residents’ deaths, and the group was placed under formal investigation in autumn 2023, notably for involuntary manslaughter. For investors, this legacy remains a risk factor in its own right: a key hearing or a new documentary revelation would weigh on the share price immediately, regardless of the quality of the operational turnaround.

The Restructuring Explained Simply

The rescue played out in three phases. Financial cleanup: debt conversions and renegotiations, fresh capital injections and sales of non-strategic assets. Operational recovery: new management, more nursing staff, quality plans published facility by facility, and closer dialogue with the government and families. Rebranding: the 2024 name change symbolically buried the old era.

So where do things stand in 2026? Operational signals are improving: first-half revenue up 6% year on year, 2026 financial targets raised at the time of that release, the Latin American exit completed, and new appointments to the finance leadership (Julia Clavel, effective September 1). But reported earnings are lagging behind: earnings per share are still expected to be negative in 2025 (−€1.31) and 2026 (−€0.53), with breakeven only just reached in 2027 (+€0.03 expected).

Who owns emeis today?

The rescue reshuffled the shareholder base. The founding families, once at the heart of the capital, have been diluted to a marginal stake; the CVC funds and Singapore’s sovereign wealth fund GIC, which came in during the successive capital increases, are among the largest shareholders, alongside former creditors whose debt was converted into shares. This is the classic restructuring pattern: yesterday’s holders (founders, retail savers) make way for those who provided the bailout.

The practical consequence for the Orpea share price: the real free float is small, which amplifies moves in both directions on limited volumes. Governance has been completely renewed: Laurent Guillot runs the group, Julia Clavel has taken over as CFO, Jean-Marc Boursier oversees group operations, and Olivier Dussopt — a former French labor minister — has been nominated as chair of the board of directors.

Financial Data and Estimates

Indicator20252026 estimate2027 estimate
Net earnings per share−€1.31−€0.53+€0.03
P/E ration/a (losses)n/a (losses)341.3
Dividend per share€0.00€0.00€0.00
1-year performance−29.22% (high €16.01 / low €9.34)

(Consensus estimates as of October 22, 2026.) The table sums up the emeis paradox: operations are recovering (revenue growth, raised guidance), but net profitability only emerges marginally in 2027 — and a multiple of 341 times that year’s estimated earnings simply means there is still almost nothing to value. The investment should be judged on the underlying trajectory, not on current multiples.

ISINFR001400NLM4
Exchange and tickerParis — EMEIS.PA
SectorHealthcare
emeis Société anonymeEMEIS.PA · Paris
9,95 €-5,24 %
Clôture précédente10,50 €
Plus haut du jour10,16 €
Plus bas du jour9,88 €
Plus haut 52 semaines16,00 €
Plus bas 52 semaines9,34 €
Volume104 081
Capitalisation1,6 Md
Rendement du dividende0,00 %
Objectif moyen des analystes16,30 €
Mis à jour le 2026-11-19 18:45:34 · Source : Yahoo · Données indicatives, ne constituent pas un conseil en investissement.

Yahoo Finance — data verified on October 22, 2026: share price and fundamentals. Market data is indicative and does not constitute investment advice.

Indicators of the operational turnaround

The consolidated income statement tells only part of the story. In 2025, revenue grew 6.1% on a like-for-like basis to around €5.9 billion, and EBITDAR jumped 19.2% to €872 million — above the announced guidance. Nursing homes, about two-thirds of the group’s business, grew by more than 8% on their own.

The momentum continued in 2026: organic growth of 6.3% in the first quarter (€1.509 billion in revenue at the end of March), occupancy back up to 89.1% (+2.1 points), and a first half that closed with EBITDAR up 18.1% and EBITDA up 46.3%. 2026 guidance now targets EBITDAR growth of more than 10%: it is this underlying trajectory — not the stock’s market past — that the market is now re-rating, or challenging.

Tableau originalDiversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Analysis: Should You Buy Orpea / emeis Stock in 2026?

The bull case

  • Re-rating potential: a median price target of €16.44, or +69% above the share price — the stock is rated a buy by 4 of the 5 analysts who still cover it (median rating 1.4).
  • Operational momentum: H1 revenue up 6% on a reported basis, 2026 guidance raised, disposals completed — the European refocus is ahead of schedule.
  • The demographic foundation: population aging creates structural demand for nursing home and care places, which the crisis of confidence has not destroyed.
  • The price already paid: after −99.98% over five years (including the consolidation) and a share price close to its 52-week low, much of the past risk is already priced in.

The bear case

  • Near-zero profitability until 2027: estimated EPS of +€0.03 in 2027 means the group will barely break even.
  • No dividend: zero shareholder payout in sight over the forecast window — the thesis rests entirely on the share price.
  • Residual reputational risk: a care group can relapse on quality of service, nursing home regulation or a media incident — the sector remains under political scrutiny.
  • Reduced liquidity: since the restructuring, analyst coverage has thinned (5 firms) and the stock can swing violently on limited volumes.

The bottom line: Orpea (emeis) stock is a high-risk sector turnaround play, best limited — like any post-restructuring situation — to a very small slice of a portfolio. The bull scenario (a re-rating toward the middle of the 52-week range) is well documented; the bear scenario (a slide back to the lows, another operational disappointment) is just as well documented.

Analyst Consensus on the Stock

As of October 18, 2026, the consensus of the 5 analysts covering emeis breaks down as follows:

RecommendationNumber of analysts
Buy4
Accumulate0
Hold1
Reduce0
Sell0

This is one of the most positive consensus readings among turnaround stocks — AlphaValue recently published a positive view on the stock. But this relative unanimity should be read with two caveats: first, only five firms cover the stock (compared with more than twenty before the scandal); second, the median targets (€16.44) mostly date from the summer rally — each quarterly release can move the Orpea share price sharply in either direction.

Orpea / emeis Stock Forecast

The central scenario of the bullish analysts has three milestones: confirmation of organic growth in Europe (occupancy rates and pricing), positive net income emerging in 2027, then the stock moving back into the €13–16 range it fell from this autumn. The bear scenario: stagnating occupancy, higher-than-expected care staffing costs, or a regulatory incident — which would push the stock below its current low.

In the meantime, the key releases to watch are: third-quarter revenue, expected in early November, the progress update on real-estate deleveraging, and above all the 2026 annual results (early 2027), which will show whether 2027 breakeven remains credible. As with any rebuilding story, disciplined management — a scaled position, a multi-year horizon and a planned exit if the thesis breaks — matters more than conviction trading.

How to Buy Orpea (emeis) Stock

If you are a beginner, our guide on how to invest in the stock market covers the basics. In practice, you can buy Orpea stock in five steps:

  1. Open an account with a regulated broker — our comparison of reliable and trustworthy trading platforms compares fees, regulation and execution.
  2. Fund the account, committing only a reasonable fraction of your capital to this stock.
  3. Find the stock using the ticker EMEIS or the ISIN FR001400NLM4 — searching for “Orpea” in some tools may return nothing since the name change.
  4. Place a limit order: essential on a volatile stock that is less liquid than the large CAC 40 stocks.
  5. Monitor the position as results come out: quarterly figures, guidance and restructuring progress updates.

Taxation (France)

In a standard securities account, capital gains are subject to the 30% flat tax (PFU) (with the option of the progressive income tax scale). In a PEA — the stock is eligible — after five years of holding, capital gains are only subject to social charges (17.2%). On a volatile thesis like this one, the choice of account matters less than the size of the position — but the PEA remains mechanically advantageous for a long horizon.

Orpea / emeis Stock FAQ

What is the Orpea share price today?

Orpea is now called emeis (ticker EMEIS, Euronext Paris). As of October 22, 2026, the stock trades at €9.69 (−2.22% on the day), close to its 52-week low of €9.34; the 52-week high is €16.01.

Why did Orpea become emeis?

After the scandal revealed in January 2022 by the book Les Fossoyeurs and the financial crisis that followed, the group was restructured and diluted, and changed its name in 2024 to turn the page: emeis was born, with a new ISIN (FR001400NLM4) and new management. Existing shares were massively diluted in this restructuring.

Should you buy emeis stock in 2026?

It is a high-risk turnaround investment: operations are improving (H1 +6% reported, guidance raised), but net income is expected to be barely positive in 2027 and there is no dividend. The remaining analysts are mostly buyers with a median target of €16.44 (+69%), but only five of them cover the stock. Keep it to a small slice of your portfolio.

Does emeis pay a dividend?

No. The dividend has been suspended since the crisis, and consensus estimates do not expect it to return before 2027 inclusive (€0.00 expected for all three fiscal years). Shareholder payouts will only come back on the agenda after a sustained return to profit.

What is the difference between Orpea and emeis?

It is the same company before and after the restructuring: emeis is the new name of Orpea, adopted in 2024 after the financial rescue. The scope has changed — international disposals, including Latin America, completed in 2026 for around €111 million — and so has the market identity (new ticker, new ISIN).

Is emeis stock PEA-eligible?

Yes. emeis S.A. is a French company listed on Euronext Paris; the stock is eligible for the PEA (French equity savings plan), with the associated tax advantages after five years of holding (only 17.2% social charges on capital gains).

Conclusion: Rebuilding Trust Is a Long Process

Orpea stock — now emeis — is the closest thing on the French market to a sector redemption bet: demographically guaranteed demand for care, a group cleaned up and refocused on Europe, raised guidance, and a remaining consensus that is clearly bullish, with more than 60% upside to the median target. On the other side: net profitability that does not yet exist, zero dividend, reduced liquidity and a reputational risk that cannot be erased by decree.

For retail investors, the conclusion is a matter of proportion and horizon: nothing here justifies a core portfolio conviction, but the stock can work as an “option on the normalization of private European care” — a minor position within a diversified turnaround strategy. The decisive milestone is the 2026 annual results: they will show whether 2027 breakeven holds.

Share prices and data as of October 22, 2026 (Euronext, Boursorama/FactSet). The estimates cited are analyst consensus figures and may be revised. This article is for information only and does not constitute investment advice: invested capital remains exposed to a risk of loss.

Suivez-nous sur Telegram